Trials / Recruiting
RecruitingNCT06807190
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 630 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Icodec | Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician. |
Timeline
- Start date
- 2025-05-30
- Primary completion
- 2027-07-31
- Completion
- 2028-01-31
- First posted
- 2025-02-04
- Last updated
- 2026-04-09
Locations
80 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06807190. Inclusion in this directory is not an endorsement.